Targeting angiogenesis in advanced non-small cell lung cancer.

Lammers PE, Horn L
J Natl Compr Canc Netw. 2013 11 (10): 1235-47

PMID: 24142825 · PMCID: PMC6628716 · DOI:10.6004/jnccn.2013.0146

Lung cancer is the leading cause of cancer-related mortality in the United States. Over the past 40 years, treatments with standard chemotherapy agents have not resulted in substantial improvements in long-term survival for patients with advanced lung cancer. Therefore, new targets have been sought, and angiogenesis is a promising target for non-small cell lung cancer (NSCLC). Bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, is the only antiangiogenic agent currently recommended by NCCN for the treatment of advanced NSCLC. However, several antibody-based therapies and multitargeted tyrosine kinase inhibitors are currently under investigation for the treatment of patients with NSCLC. This article summarizes the available clinical trial data on the efficacy and safety of these agents in patients with advanced lung cancer.

MeSH Terms (12)

Angiogenesis Inhibitors Antineoplastic Agents Biomarkers Carcinoma, Non-Small-Cell Lung Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Humans Lung Neoplasms Neoplasm Staging Neovascularization, Pathologic Prognosis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: